Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So far this stock has been a huge disapointment. But there is so much smoke. There soon should be a fire of some size.
Divine Skin To Begin Manufacturing Its OTC Pain Reliever
MIAMI BEACH, Fla., June 26, 2012 -- Divine Skin Inc. (DSKX) (OTC Bulletin Board: DSKX) Divine Skin today announced that it was granted a Drug Enforcement Agency license in partnership with its manufacturing partner to produce and distribute Ephedrine containing drugs and other controlled substances.
The Company has started working on a new OTC analgesic, which it believes could provide an alternative to current OTC pain relievers. Receiving this mandatory license is the final step in commencing manufacturing of its OTC pain reliever.
In the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, anti-arthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4 billion in 2009, according to an August 2010 report published by the US Census Bureau.
About Divine Skin
Divine Skin Inc. is a leader in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices.
DS Laboratories, its flagship brand, offers high-performance topical solutions for a wide range of personal care needs. Bioavailability is enhanced through Nanosome encapsulation (www.DSLaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (SigmaSkin.com).
Polaris Research Laboratories makes high-potency hair-growth formulas (Polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers. (ThePureGuild.com).
In some of the companies I have financed, Some of them took over 4 years. Depends on what they will accept or what they want you to change before they will give one to you. If I remember right. The upside to the delay is no one can look at it before its issued. Then its public information and everyone then figures out how to get around it.
Annual CEO Letter to Wound Management Technologies Shareholders
FORT WORTH, Texas, May 29, 2012 PRNewswire-FirstCall –Chairman of the Board and Chief Executive Officer of Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK), Robert Lutz, Jr. issues his first letter to investors on the state of companies progress since his appointment earlier this year.
Dear Wound Management Technologies Shareholder,
After being part of the Wound Management team for less than two months, I wanted to report on our progress in this short time frame. First, our management team has developed a focused three year strategic plan and budget. Our plan calls for an attainable and disciplined approach for marketing and sales of our primary product line, CellerateRX®, via three major markets: Hospitals/Operating Rooms, Wound Care Centers and Long Term Care Facilities / Home Health Agencies. We believe that having products that address all three markets independently is imperative. Secondly, we are experiencing sales growth that, should it continue in line with current projections, would allow us to achieve sustained positive cash flow from operations by year end.
We have been successful in retaining the internal sales management team and network of distributors established by Juventas. They market and sell our products primarily in Hospitals and Wound Care Centers. The Hospital channel singularly represents a significant opportunity as our powder is now being used to facilitate the healing of surgical wounds in “high risk” patients throughout the entire surgical specialty spectrum. Through this effort, we have a rapidly expanding group of trained field sales representatives working for 37 contracted Wound Management medical distributors. This gives us national presence not only in the Hospital environment; they are also positively impacting the demand of CellerateRX in Wound Care Centers, Long Term Care Facilities, Home Health Agencies, and Physician offices nationwide. Importantly, we have been able to gain market acceptance in the “cost sensitive” Hospital environment, positioning CellerateRX as a positive wound care solution, both in associated product and labor costs and in effectiveness in healing surgical, chronic and acute wounds.
We remain committed to expanding our market reach with the help of strategic partners and have an updated agreement, in principle, with WellDyne (a health care company with over 20 million patients in its network). WellDyne is dedicating a sales team to CellerateRX to take our gel product directly to more Physicians, Long Term Care Facilities, Home Health Agencies, Pharmacies and patients. Douglas Taylor Exec VP, Sales and Market Development, expressed “WellDyne is extremely excited about the opportunity to market CellerateRX to our growing patient base. The product’s cost profile and clinical advantages will improve WellDyne’s ability to serve patients with diabetic ulcers and other wound care conditions”.
We also are refocusing our efforts and attention to address and emphasize quality distributors in international markets so that we can apply our US surgical market expertise to other countries. Providing value, improving patient outcomes and quality of life, and the associated cost reductions are a common vision shared by many country’s healthcare systems.
Preparing for the future expanding role of our products, we are studying the feasibility of three other markets where CellerateRX formulas could have great sales potential: dental, dermatology / plastic surgery and sunburn relief. We are committed to the completion of our feasibility studies and plan to launch a product into at least one of these areas in 2013 in conjunction with a strategic partner.
In addition to our wound care product line, the Resorbable Bone Wax division will have our new bone wax approved and ready for the market by year end 2012. We are currently planning our sales strategies for this exciting new product to add to our sales distribution model and are exploring partnering opportunities to properly address complete sales penetration of all potential markets. This is in addition to the products currently in development by BioStructures, our licensed partner for bone void filler products based on our patent.
As you can see it is a busy and productive time for Wound Management. We are committed to increasing our products’ market share in our existing market segments while discovering and creating new markets where we can provide efficacy, value and cost savings globally. Our new management team is diligently honing and redefining our complete sales processes for precise execution of our sales initiatives and 3 year plan to meet our goal of near term attainment of positive cash flow from operations.
Increasing shareholder value is not only our goal; it is a direct measurement of our ability, talent and efforts to seize the opportunities that our products have in the evolving healthcare market. I very much look forward to more communication with you about our progress and success in the timely achievement of our sales, marketing and management objectives. Where many see challenges, we see opportunity. We are very excited about executing our plan to deliver unique, high quality, cost effective products worldwide.
Respectfully,
Bob Lutz, Jr
Chairman & CEO
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Follow us on: FACEBOOK | TWITTER | LINKEDIN
Safe Harbor Statement
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
Tel: (817) 820-7077
Fax: (888) 746-7566
Email: info@wmgtech.com
IT should go straight up from here. I sold the last of my 500000. Will take the big beating and walk away.
The product is not the problem. The problem is we still have the same YAHOO running the company. He tries to micro manage every thing. He takes no advice from any one. This means he spends a great amount of time reinventing the wheel. On the up side. Rumor has it. He has now hired a consultant to clean it all up and move it to a better exchange.
I have no idea what they are doing. All I know is sales are going up. Rumor has it sales may hit 30 million this year. Hard to belive, but that would take it to a buck at least.
MIAMI BEACH, Fla., April 11, 2012 -- Divine Skin Inc. (DSKX) (OTC Bulletin Board: DSKX), a leading developer of personal-care products, announced that it closed a $1.5 million line of credit with MidCap Business Credit LLC in a move that will continue to fuel the explosive growth the company is experiencing.
Divine Skin CEO Daniel Khesin stated, "Securing the right funding to finance our growth is just one more step in the right direction as we continue to see stellar demand for our products. Having easier access to funds will allow us to capitalize on opportunities for growth without diluting our shareholders through equity financing."
Richard Mount, president and founder of MidCap Business Credit LLC, commented, "It's always exciting to see companies like Divine Skin really start to take off. We're very pleased to be working alongside Divine Skin, providing the credit that it requires to continue to expand. We look forward to a long relationship."
Khesin added, "We continue to see significant opportunities for business growth within our sector. Having a secured funding source in place allows us to focus our energies on generating sales and building the business more quickly. We are extremely excited about this new relationship we are building with MidCap."
About MidCap Business Credit LLC
MidCap provides commercial loans necessary to support growth and assist business through temporary financial setbacks. Its asset-based commercial loans range from $1 million up. Its collateral-monitoring systems, along with its senior management team's direct involvement, make available the service and working capital needed. MidCap is a true asset-based lender, whose focus is lending on the value of the borrower's assets that will secure the loan. MidCap also supports the financing of foreign accounts receivable and finances accounts receivable denominated in international currencies. The company's headquarters are located in West Hartford, Connecticut (www.MidCapCredit.com).
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).
Divine Skin (DSKX) now on Facebook
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com
The reason is they have a lot of stock and never know for sure if the deals they are making will work. So they sell part of there holdings to take out there orignal investment. They hire people like UDE when they are starting out. They need the exposure. They also need the money from the early stock sales to get the company to scale. People take advice from people like UDE because of there past performance record. A few years ago they were hot. They get paid in stock. So you never know when thet are sellers or buyers. The company is still too small to atract major investors. But three of 4 more quarters of good growth, and this may start to take off.
Rapidly Expanding Distribution Network Contributes to Revenue of $9.7 Million, Up 77 Percent Over 2010
MIAMI BEACH, FL-- (04/04/12)- Divine Skin Inc. (OTC.BB: DSKX.OB), which formulates, develops, and markets new personal-care products, announced full-year 2011 results. Compared to 2010, highlights of the year-end earnings report include:
-- Net revenue increased to $9.7 million, up $4.2 million.
-- Cash balance increased to $1.3 million, up $1.1 million.
-- Inventory increased to $2.0 million, up $900,000.
-- Shareholders' equity increased to $5.0 million, up $2.6 million.
-- Assets increased to $6.2 million, up $3.1 million.
During the year, the company added several new distributors in the United States and around the world.
Divine Skin CEO Daniel Khesin stated, "While Divine Skin set several new records in 2011, today's announcement is just an indication of what's to come. We believe the demand for our innovative brands and products will continue to accelerate. With this increased demand, we believe we will continue to add significant value for our shareholders.
"Our hair-stimulating products have entered the daily routines of hundreds of thousands of customers," Khesin continued. "Recent clinical studies have shown that our topical treatments are achieving nearly 100 percent response during early-stage hair loss, which makes a big difference in the lives of many users."
Financial position
Net revenue increased to $9,672,861 for 2011, up $4,228,056 or 77 percent from the $5,444,804 of the previous year.
Assets increased to $6,103,992, as of December 31, 2011, up $3,160,132 or 107 percent from the $2,943,860 of the previous year.
Inventory levels increased to $2,174,784 as of December 31, 2011, up $993,105 or 84 percent from the $1,181,679 of the previous year.
Accounts receivable increased to $1,888,453 as of December 31, 2011, up $1,150,499 or 155 percent from the $737,954 of the previous year.
Working capital reached $4,306,774 as of December 31, 2011.
Net loss reached $980,892 for 2011, up $831,079 or 531 percent from the loss of $149,813 a year earlier.
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).
The YAHOOS gave them selfs 5 of 6 million shares at .01. It is going to take some time to work that off.Thats why it has fell so far. That being said. If they come out with some good news. We could start to go back up.
The odds are in your favor only if your right and your short. Sounds like you don't own a share. So no matter what happens, you will not make or lose a dime. As far as the rest of your comments, That was then and this is now. I have paid my money and am now taking my chances.
And your point ?
Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder
FORT WORTH, Texas, March 22, 2012 PRNewswire-FirstCall – The Board of Directors of Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leading innovator in advanced wound care solutions, announced today that Robert Lutz, Jr. has been appointed to the Board of Directors of the Company. In addition, Scott A. Haire has resigned as Chairman of the Board of Directors and as Chief Executive Officer of the Company, and Deborah Jenkins Hutchinson has resigned as President of the Company, and Mr. Lutz has been elected as the new Chairman of the Board, Chief Executive Officer and President of the Company. Mr. Haire and Ms Jenkins Hutchinson will continue on as directors of the Company.
Mr. Lutz has extensive management and leadership experience with both public and private companies, including subsidiaries of Liberty Corp, American Express and AMRESCO. Mr. Lutz brings a proven track record in significantly growing the revenue and net income of companies, and has significant experience in negotiating business contracts with Fortune 100 firms, including IBM and AT&T.
In conjunction with Mr. Lutz joining Wound Management, the Company has reacquired the North American distribution rights for its CellerateRX® advanced wound care powder from Juventas, LLC. By doing so, Wound Management will be able to create a unified sales and distribution program for CellerateRX and its other products. This reacquisition includes the acquisition of a newly-packaged specialized CellerateRX powder kit for use in the biologic surgical closure market that was successfully established by Juventas. As a result, the management agreement between Wound Management and Juventas previously announced in November 2011 has also been terminated, and Juventas is no longer involved with Wound Management.
“After extensive due diligence with Wound Management and its core subsidiary, Wound Care Innovations, LLC, I am very impressed with the CellerateRX wound care products line and I believe the Company can capture a significant market share in the worldwide wound care products market,” said Mr. Lutz. “In addition to their current product lines, Wound Management has other significant opportunities with its Resorbable Orthopedic Products subsidiary to explore. I plan to announce a comprehensive strategic plan in the near future that will discuss these ideas, as well as other strategic initiatives I plan to introduce to the company.”
“Bob’s strong leadership, exceptional strategic vision, and past corporate performance will allow Wound Management to capitalize on its opportunities in the medical marketplace, while building shareholder value,” said Mr. Haire. “I, along with other majority shareholders, support and welcome Bob to lead the Company forward.” Mr. Haire will remain as a major shareholder of Wound Management and will continue to assist the company in its strategic direction and future growth.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Follow us on: FACEBOOK | TWITTER | LINKEDIN
Safe Harbor Statement
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
MIAMI BEACH, Fla., March 22, 2012 -- Today Divine Skin Inc., (OTC Bulletin Board: DSKX), a leading developer of cutting-edge biotechnology for hair and skin, announced that it had signed a letter of intent to acquire 100 percent of Divine Skin Laboratories SA de CV in stock. In 2011, the Mexican company represented nearly 10 percent of Divine Skin's revenue. It has been a distributor of Divine Skin product for more than three years, with sales growing quickly year over year.
Divine Skin CEO Daniel Khesin stated, "I believe this move will not only boost our current revenue but also be a significant asset to Divine Skin's human resources. We've worked with Divine Skin Laboratories SA de CV for many years, and it has proven to be a very strong partner. We value this relationship, and I know that this acquisition will add significant value to both entities."
In Mexico, Fernando Tamez, CEO of Divine Skin Laboratories SA de CV, said, "I'm thrilled to take a more active role in Divine Skin Inc. I started the distribution of DS Laboratories products three years ago and have seen this market grow into a sizable revenue stream, with enormous continued upside for growth. I think we can continue to double our revenues every year for the next few years. Mexico is a huge market for these advanced products. Divine Skin offers formulas unlike anything else we have in Mexico, and I am looking forward to continuing to expand this business."
The terms of the agreement will be made public once the transaction is complete. It is scheduled to close in the second quarter of 2012.
About Divine Skin Laboratories SA de CV
Divine Skin Laboratories SA de CV was formed in 2008 in Mexico City. It sells and distributes DS Laboratories products exclusively to a network of physicians throughout Mexico. It has an office and 40 employees in Mexico City.
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).
Not the update I was looking for. But add this one to the one I was looking for and I am a little sorry for selling 2 million shares last week. O well, cant have it both ways. Made big bucks and still have a ton left.
Industrial Nanotech, Inc. Issues Update
Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions is pleased to update its shareholders and supporters of recent activity and progress. The Company has been working diligently to cultivate several valuable sales channels, identify new markets and sources of revenue, and has produced tangible results including initial implementation and resulting installations for corporate and government projects.
1. Upgrading the energy efficiency of windows, especially in large older factories is becoming a very significant source or revenue for the Company. Older factories were built with “walls of windows”, which were effective at letting light in, but very energy inefficient. Applying the Company’s translucent Nansulate(R) Energy Protect is a cost effective solution that still lets the light in, but reduces heat transfer through the glass. As an example, a factory in Ohio utilized Nansulate(R) on their windows and the result was a real dollar energy saving amount equal to eight times the amount of their original investment in Nansulate(R) was achieved in the first four months subsequent to the application.
According to the U.S. Department of Energy, commercial and residential buildings account for nearly 40 percent of energy used in the U.S. With energy costs soaring, the green building materials industry has grown to $156 billion a year. With their coatings already being used on other areas of the building envelope - walls, roofs, ceilings, skylights - to reduce energy costs, the Company is aggressively pursuing factory windows in older buildings, as well as other building applications.
“Windows are one of the largest energy wasters in any building as they allow a great deal of heat transfer,” stated Francesca Crolley, VP Business Development for Industrial Nanotech, Inc. “There are thousands of factories and commercial buildings built with single pane windows, and building owners are finding that replacing these windows is cost prohibitive. Our technology offers an affordable and effective way for the existing windows to be insulated easily with a spray on application that can also be sprayed over frames to further reduce thermal bridging. Our Energy Protect coating allows through over 90% of the visible light, while reducing heat transfer and resulting energy costs, and also reducing UV light, which is desirable by museums trying to protect artwork from fading.”
2. The Company has expanded into the historical preservation and restoration market. Upcoming projects include a U.S. military museum and a New York State historic restoration project to install the Company’s clear lead encapsulation product, Nansulate(R) LDX. Additionally, the company has submitted an abstract to speak at the Annual Association for Preservation Technology International (APT) Conference held in September, to illustrate the benefits that nanocoatings can provide for preservation and restoration of historic sites.
3. Industrial Nanotech moved into the OEM market, including integration of the Company’s Patented Nansulate® coatings into building products. Application of Nansulate® by several large major customers to their products at the factory is expected to begin in the very near future and will substantially impact revenues.
4. A multi-year project with a Southeast Asian government is beginning by midyear, resulting in a high dollar volume marque project for resistance of mold growth and surface protection on a high profile building which is well known throughout the region and globally. This will add to the Company’s profile of providing multi-solution nanotechnology products which not only save energy, but perform a variety of other tasks, such as mold resistance, corrosion prevention, moisture resistance, UV resistance, chemical resistance and lead encapsulation.
5. One of the Company’s European distributors has been working with a major provider of rail transportation, who after completing initial testing, has approved a field study over several tunnels for Nansulate(R) coatings to trial the ability of the coating to prevent icicle formation in tunnels and overpasses in order to reduce train derailment due to ice dropping on rail tracks. This study is ongoing and expected to be completed in 2012.
6. The company has been presenting their nanotechnology based solutions to a number of fortune 500 companies and companies on the Dow Jones Sustainability Indexes over the past two years. Many of these companies have completed or are close to completing initial due diligence projects at U.S. based factories with the technology, and the Company anticipates several multi-plant projects beginning in 2012 and continuing into 2013 and beyond.
“We have been working diligently to replicate the model that we used with global textile manufacturer, Coats plc,” stated Ms. Crolley. “Initial due diligence projects for energy saving calculations were completed as a first step at two of their facilities, which then resulted in a global sustainability project with our Nansulate(R) coatings being used to insulate equipment in their factories throughout 28 countries. We have the ability to drastically reduce energy intensity in manufacturing with an extremely short payback period, and we have been taking that message to plants and factories throughout North America for the past several years. With the economy beginning to recover, we are seeing the fruits of those efforts begin to be realized.”
For further information on Nansulate(R) nanotechnology based coatings and sustainable solutions visit: www.nansulate.com.
About Nansulate(R)
Nansulate(R) is the Company's patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate(R) Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.inanotk.com) and (www.nansulate.com). Blog: www.nansulate.com/nanoblog, Twitter: www.twitter.com/NanoPioneer, Facebook: www.facebook.com/Nansulate.
About Industrial Nanotech Inc.
Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Green Building Council. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.
I know not why, but I have been adding all week.
It is 33%. I will take that any day.
That is one of the reasons I am in this stock in a big way.
Lets use a little imagination. If we can accept that the product works. We can extrapolate from that point. The product is extreamly thin. While most other sprayed on products are very thick. For example, sideing for houses. They could coat the inside and out side. This would add very little weight to the product. Being done at the time of production, cost would be insignicant. From there. Roof Tiles Lumber Bricks Concrete Blocks Drywall and on and on. Best of luck to all.
THE OLD GUY
Nice find CAPTAIN. It always bugs me how people can buy stock in some companies that have zip for sales. Low margin product and a small nitch market. While companies like IWEB and DSKX that have a much greater chance of showing the potential to be a 10 bagger get so little support. Congratulations to all longs. It looks like our long wait is going to be worth it.
BEST OF LUCK TO ALL
THE OLD GUY
Looks like you will get it and then some. Having financed 18 start up companies in my time. Before my retirement, I will take a guess and say we go sideways for now. The reason from my past experience in these matters would be,they are (hung up in legal).That was heard in 98% of all the delays I had to put up with in working with small companies. BEST OF LUCK TO ALL
Divine Skin's NutraOrigin Brand Sells to United Natural Foods
MIAMI BEACH, Fla., Feb. 28, 2012 --Today Divine Skin Inc. (OTC Bulletin Board: DSKX) announced that it has taken its first NutraOrigin supplement order from United Natural Foods, Inc. (NWFI).
"We are thrilled to be working with United Natural Foods," said Daniel Khesin, Divine Skin's CEO. "We believe this relationship will take the NutraOrigin brand to a new level of distribution, and we are looking forward to a very rewarding relationship together."
About United Natural Foods, Inc.
United Natural Foods, Inc., together with its subsidiaries, engages in the distribution and retail of natural, organic, and specialty foods, as well as non-food products in the United States and Canada. The company distributes approximately 60,000 products in six product categories, including grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and food service products, and personal care items.
The company also imports, roasts, packages, and distributes nuts, dried fruits, seeds, trail mixes, granola, natural and organic snack items, and confections, as well as offers Blue Marble Brands through bulk sale and private-label packaging.
United Natural Foods customers include independently owned natural products retailers, supernatural chains, conventional supermarkets, and mass-market chains, as well as food-service and international customers outside Canada.
The company was founded in 1976 and is headquartered in Providence, Rhode Island. It states that it has 6,900 employees and revenues of $4.69 billion in its 2011 fiscal year, which ended July 30.
About NutraOrigin
Manufactured in the United States, the nutritional supplements of NutraOrigin set new standards of efficacy because the potent formulas are engineered to address real-world health concerns of consumers as expressed via online search data.
The Omega line, demonstrated in clinical trials to boost mental function, now comprises 28 SKUs, which include softgels with fish oil, krill oil, and other sources of omega-3 fatty acids, plus shakes in pleasant fruit flavors, gummies for kids, and oils for pets.
The Clinical line has 24 SKUs. Comprehensive blends target users concerned about aging, fatigue, depression, insomnia, headaches, glucose, cholesterol, obesity, osteoporosis, oxidation, indigestion, inflammation, immunity, mobility, menopause, memory, sight, hair, erectile dysfunction, premenstrual syndrome, and benign prostatic hyperplasia.
The Vitamin line, with 11 SKUs, includes tablets, softgels, and gummies targeted to men, women, kids, and seniors.
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).
ENZR has a bunch.
Lots of rumors of big sales pending. Two or three other companies intrested in this product to apply to their products. But there are 500 million shares out there. At 4 cents, a market cap of 20 million on a company that has very little sales and zip for profit. This turkey is not going to run away to the upside any time soon. Do I think it will go up. YES But buy it with the knowledge that it will take some time to make a major move. Buy here or a little less, but be prepared to sit.
Not going to happen.
Try stockhouse.com The pmi board talks about bkn all the time.
I am not so sure. The boys out here at SHADY PINES are saying they are the only one that holds a process patent to spray this stuff on. Thats where the value comes into play. I don't know if its true or not. Also not smart enought to find out. But if true. Other people in this industry would step up to get the rights to use it.
Mcknight was in charge of IR and placing the stock into investors hands. They are being replaced May first by raymond James. A lot bigger and more connected.
Shell is here because they were on these blocks before the goverment was over thrown and they had to leave. Its great they came back. If they did not it would look bad. Manas has control of about 80% of all the oil properties that are available at the present. It don't get no better than that. With Raymond James taking over May first. They will be pushing it to all the funds.
Divine Skin Q4 Tops $3 million; 2011 Revenue Reaches $9.6 million, Up 78% Over 2010
MIAMI BEACH, Fla., Feb. 9, 2012 -- Today Divine Skin (OTC Bulletin Board: DSKX) released preliminary revenue figures for the fourth quarter, $3.1 million, up 63 percent over the same quarter of 2010 and up 48 percent over the third quarter of 2011. For the year 2011, revenue totaled $9.6 million, up 78 percent over 2010.
Divine Skin CEO Daniel Khesin said, "While we experienced nearly triple-digit growth in 2011, we are far from satisfied with this result. We believe this number will improve significantly as we continue to optimize logistics.
"Our formulas are very complex, and bringing these one-of-a-kind products to market is a challenge," he continued. "The issue is our top priority going forward, and we are very excited about our prospects for 2012."
Divine Skin had a busy year. Notable achievements include:
SALONS. In 2011 Divine Skin established new agreements with 19 salon distributors around the United States to sell its flagship brand, DS Laboratories. The new partners, each a leader in its market, employ a network of nearly 1,000 sales consultants who reach a combined 150,000 salons. In 2011 they penetrated 10 percent of their outlets, and in 2012 they project to have 30 percent selling the brand. Salon distribution, which represented a small fraction of sales prior to 2011, has become Divine Skin's fastest-growing segment, responsible for nearly half of its domestic business.
FANTASTIC SAMS. DS Laboratories installed more locations of the huge Fantastic Sams chain of salons, supplying unique product, professional training, and promotional assistance.
NEIMAN MARCUS. Prestigious fashion retailer Neiman Marcus picked up Divine Skin's super-premium Sigma Skin line for hair and skin.
WHOLE FOODS. The NutraOrigin line was tested successfully in Whole Foods, a chain of 297 retail stores in the United States plus seven in Canada and six in the United Kingdom.
NANOXIDIL. The company introduced a new compound, Nanoxidil, engineered to surpass minoxidil for efficacy and tolerability. It debuted in the new topical treatment Spectral.DNC-N.
ASTRESSIN-B. DS Laboratories became the first biotech brand to commercialize a hair-growth treatment based on astressin-B, a peptide (protein fragment) newly discovered to regrow hair on bald mice. It debuted in the new Spectral.F7.
API SOLUTION 9. The Polaris Research brand rolled out API Solution 9, a customizable topical kit to be sold by physicians. It delivers unprecedented concentrations of minoxidil, finasteride, and alfatradiol, and it has no direct competitor.
ORAL ANALGESIC. Divine Skin announced its foray into pharmaceuticals with an oral analgesic to compete with Tylenol, Advil, and aspirin. Like the company's other products, it targets the market that appreciates more advanced biotechnology.
NUTRAORIGIN. Expanding into nutritional supplements, Divine Skin acquired rights to NutraOrigin, with 63 formulas that can be incorporated easily into any health regimen.
BRAZIL. A new Brazilian distributor conducted the successful trials and earned the required certificates needed to import product into that burgeoning market of 201 million eager consumers.
RANBAXY LABORATORIES. Divine Skin announced a global partnership with India's largest pharmaceutical company, Ranbaxy Laboratories, to sell DS Laboratories products worldwide.
CAPITALIZATION. Divine Skin secured new capital through Littlebanc Advisors to be used to build mounting inventory and service expanding distribution.
AUDITORS. Top-30 auditing firm Cherry, Bekaert & Holland LLP began advising the company, bringing valuable experience with publicly traded manufacturers and lending greater credibility to financial statements.
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.dslaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).
NutraOrigin blends nutritional supplements that address the health concerns expressed by consumers, including fatigue, headache, obesity, mobility, menopause, erectile dysfunction, and others. In clinical trials for the US government, its Omega line proved to enhance mental function (www.nutraorigin.com).
I am not the happiest camper in town. Holding a hundred thousand shares at 1.44 average. But maybe this will be the exposure that is needed. Being on a big exchange should help a lot.
From what I hear out here at Shady Pines. There was a fund that was forced to liquidate along with two large holdings by two investors that pasted on. This dumped 18 million shares on to a weak market. That is now past and they will start drilling in the next 30 days. Also they may announce a major is going to sign to drill the deep targets in the next 60 days. If you take the cash on hand and the value of the PMI stock. Mnap is worth .40 cents a share. It is way under valued. I own a ton and would buy more if funds were available.
BEST OF LUCK TO ALL
THE OLD GUY
I am not as smart as you. I sold a ton at .33. I could not pass up a 45% profit. I have lots left, but will wait for at least .60 before I sell more.
The way it is now trading. Says, back up the truck and filler to the top.
Use post 370
Sounds like you.
It is after all a peney stock. A hope and a prayer. Why would a talented investor such as yourself even waste your time here. You must know that T&A analyse on penney stocks is far from valid. Why not move on to others that are better for your trading methods. Let us poor fools sit here in peace with our HOPES and dreams. BEST OF LUCK TO ALL
THE OLD GUY